SLDB Stock Overview
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States.
Solid Biosciences Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$6.58|
|52 Week High||US$30.75|
|52 Week Low||US$5.89|
|1 Month Change||7.69%|
|3 Month Change||-31.46%|
|1 Year Change||-74.93%|
|3 Year Change||-89.87%|
|5 Year Change||n/a|
|Change since IPO||-98.06%|
Recent News & Updates
Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest ResultsApr 30
Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) EstimatesApr 28
We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn RateMar 17
Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth PlansOct 28
We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn RateJul 13
We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash WiselyMar 17
|SLDB||US Biotechs||US Market|
Return vs Industry: SLDB underperformed the US Biotechs industry which returned -16.1% over the past year.
Return vs Market: SLDB underperformed the US Market which returned -20.5% over the past year.
|SLDB Average Weekly Movement||6.9%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: SLDB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: SLDB's weekly volatility (7%) has been stable over the past year.
About the Company
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company’s lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients’ muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids.
Solid Biosciences Inc. Fundamentals Summary
|SLDB fundamental statistics|
Is SLDB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SLDB income statement (TTM)|
|Cost of Revenue||US$12.99m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-11.87|
|Net Profit Margin||-795.16%|
How did SLDB perform over the long term?See historical performance and comparison